Research ExplorerPublicationsSulindac derivatives inhibit cell growth and induce apoptosi...

Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients

Standard

Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients. / Frahm, Silke; Kurtz, Andreas; Kluwe, Lan; Farassati, Faris; Friedrich, Reinhard E; Mautner, Victor F.

In: CANCER CELL INT, Vol. 4, No. 1, 17.05.2004, p. 4.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Frahm, S, Kurtz, A, Kluwe, L, Farassati, F, Friedrich, RE & Mautner, VF 2004, 'Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients', CANCER CELL INT, vol. 4, no. 1, pp. 4. https://doi.org/10.1186/1475-2867-4-4

APA

Frahm, S., Kurtz, A., Kluwe, L., Farassati, F., Friedrich, R. E., & Mautner, V. F. (2004). Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients. CANCER CELL INT, 4(1), 4. https://doi.org/10.1186/1475-2867-4-4

Vancouver

Frahm S, Kurtz A, Kluwe L, Farassati F, Friedrich RE, Mautner VF. Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients. CANCER CELL INT. 2004 May 17;4(1):4. https://doi.org/10.1186/1475-2867-4-4

Bibtex

@article{d0b5b9faae33451d9c68a524e1162404,
title = "Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients",
abstract = "BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are neoplasms leading to death in most cases. Patients with Neurofibromatosis type 1 have an increased risk of developing this malignancy. The metabolites of the inactive prodrug Sulindac, Sulindac Sulfide and Sulindac Sulfone (Exisulind) are new chemopreventive agents that show promising results in the treatment of different cancer types. In this study we examined the antineoplastic effect of these compounds on primary cells derived from two MPNSTs of Neurofibromatosis type 1 patients. RESULTS: Exisulind and Sulindac Sulfide showed a dramatic time- and dose-dependent growth inhibitory effect with IC50-values of 120 microM and 63 microM, respectively. The decrease in viability of the tested cells correlated with induction of apoptosis. Treatment with 500 microM Exisulind and 125 microM Sulindac Sulfide for a period of 2 days increased the rate of apoptosis 21-27-fold compared to untreated cells. Reduced expression of RAS-GTP and phosphorylated ERK1/2 was detected in treated MPNST cells. Moreover, elevated levels of phosphorylated SAPK/JNK were found after drug treatment, and low activation of cleaved caspase-3 was seen. CONCLUSIONS: Our results suggest that this class of compounds may be of therapeutic benefit for Neurofibromatosis type 1 patients with MPNST.",
author = "Silke Frahm and Andreas Kurtz and Lan Kluwe and Faris Farassati and Friedrich, {Reinhard E} and Mautner, {Victor F}",
year = "2004",
month = may,
day = "17",
doi = "10.1186/1475-2867-4-4",
language = "English",
volume = "4",
pages = "4",
journal = "CANCER CELL INT",
issn = "1475-2867",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients

AU - Frahm, Silke

AU - Kurtz, Andreas

AU - Kluwe, Lan

AU - Farassati, Faris

AU - Friedrich, Reinhard E

AU - Mautner, Victor F

PY - 2004/5/17

Y1 - 2004/5/17

N2 - BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are neoplasms leading to death in most cases. Patients with Neurofibromatosis type 1 have an increased risk of developing this malignancy. The metabolites of the inactive prodrug Sulindac, Sulindac Sulfide and Sulindac Sulfone (Exisulind) are new chemopreventive agents that show promising results in the treatment of different cancer types. In this study we examined the antineoplastic effect of these compounds on primary cells derived from two MPNSTs of Neurofibromatosis type 1 patients. RESULTS: Exisulind and Sulindac Sulfide showed a dramatic time- and dose-dependent growth inhibitory effect with IC50-values of 120 microM and 63 microM, respectively. The decrease in viability of the tested cells correlated with induction of apoptosis. Treatment with 500 microM Exisulind and 125 microM Sulindac Sulfide for a period of 2 days increased the rate of apoptosis 21-27-fold compared to untreated cells. Reduced expression of RAS-GTP and phosphorylated ERK1/2 was detected in treated MPNST cells. Moreover, elevated levels of phosphorylated SAPK/JNK were found after drug treatment, and low activation of cleaved caspase-3 was seen. CONCLUSIONS: Our results suggest that this class of compounds may be of therapeutic benefit for Neurofibromatosis type 1 patients with MPNST.

AB - BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are neoplasms leading to death in most cases. Patients with Neurofibromatosis type 1 have an increased risk of developing this malignancy. The metabolites of the inactive prodrug Sulindac, Sulindac Sulfide and Sulindac Sulfone (Exisulind) are new chemopreventive agents that show promising results in the treatment of different cancer types. In this study we examined the antineoplastic effect of these compounds on primary cells derived from two MPNSTs of Neurofibromatosis type 1 patients. RESULTS: Exisulind and Sulindac Sulfide showed a dramatic time- and dose-dependent growth inhibitory effect with IC50-values of 120 microM and 63 microM, respectively. The decrease in viability of the tested cells correlated with induction of apoptosis. Treatment with 500 microM Exisulind and 125 microM Sulindac Sulfide for a period of 2 days increased the rate of apoptosis 21-27-fold compared to untreated cells. Reduced expression of RAS-GTP and phosphorylated ERK1/2 was detected in treated MPNST cells. Moreover, elevated levels of phosphorylated SAPK/JNK were found after drug treatment, and low activation of cleaved caspase-3 was seen. CONCLUSIONS: Our results suggest that this class of compounds may be of therapeutic benefit for Neurofibromatosis type 1 patients with MPNST.

U2 - 10.1186/1475-2867-4-4

DO - 10.1186/1475-2867-4-4

M3 - SCORING: Journal article

C2 - 15147581

VL - 4

SP - 4

JO - CANCER CELL INT

JF - CANCER CELL INT

SN - 1475-2867

IS - 1

ER -